ClinicalTrials.gg
Not yet recruitingNCT07942103Updated Nov 17, 2026

Study on the Construction and Implementation Effect of a Traditional Chinese Medicine-Based Mental-Physical Comorbidity Linked Health-Management System of "Hospital-Community-Family" for Breast Cancer Patients

An interventional study of Acupuncture in Breast Neoplasms, sponsored by First Teaching Hospital of Tianjin University of Traditional Chinese Medicine. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · Not applicable, Interventional, and Health services research

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,930 studies in Breast Neoplasms with a site in China — 868 open to participants now, 1,065 under way, 210 of them phase 3. Breast Neoplasms · China.

Planned enrollment
527th of 1,520
216 · median 120
Started
2026
with 186 others
No phase
327 of 1,930
170 open now
Primary completion
2028-12
later than 901 of 1,064 live
Registered
1,925th of 1,930
by date

Among the 1,930 studies in Breast Neoplasms with a site in China, this one is the 527th largest by planned enrollment of the 1,520 interventional ones that give a count, is one of 187 that started in 2026, is one of 327 with no phase, reaches primary completion later than 901 of the 1,064 other live ones, and was the 1,925th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

868 of the 1,930 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

863 more — sign in →

All 868 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,930 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

In this study, the effect-implementation mixed research design was adopted. The patients were assigned to the intervention group and the control group at a ratio of 2 : 1 by the central stratified randomization method. The stratification factors were four phenotypes of psychosomatic symptoms ( anxiety and depression, sleep disorders, fatigue and mixed symptoms ). The intervention group was determined by the three-stage conversation model of doctor-patient joint decision-making, and the personalized acupuncture intervention program was determined. Combined with the patient 's own needs and service accessibility, the hospital intervention subgroup or the medical-social-home intervention subgroup scenario was determined. The control group was given routine nursing. Because the intervention requires informed interaction between doctors and patients, only outcome evaluators and data analysts are blinded. The intervention period was 8 weeks of treatment and 4 weeks of follow-up, a total of 12 weeks. Based on the evaluation of the effect of acupuncture intervention on the improvement of psychosomatic symptoms, the study was guided by the CFIR framework to evaluate the implementation of the hospital intervention subgroup and the medical-social-family intervention subgroup formed after the joint decision-making of doctors and patients, identify the implementation obstacles and promotion factors, and evaluate the implementation outcomes such as acceptability, feasibility, implementation loyalty and coverage.

03

Conditions studied

  • Breast Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female, aged 18-70 years
  2. or cytologically confirmed breast cancer (AJCC 8th Edition Stage 0-IV)
  3. At least one psychosomatic symptom meeting the following criteria:

    • Anxiety or depression: Hospital Anxiety and Depression Scale (HADS) anxiety or depression subscale ≥ 8
    • Sleep disorder: Pittsburgh Sleep Quality Index (PSQI) total score ≥ 8
    • Cancer-related fatigue: Brief Fatigue Inventory (BFI) total score ≥ 4
  4. Expected survival ≥ 1 year
  5. Alert, conscious, with basic communication ability, able to complete questionnaire assessments
  6. Signed by patient or legal guardian

Exclusion criteria

Exclusion Criteria:

  1. Severe mental disorders (e.g., schizophrenia, bipolar disorder) or lack of civil capacity
  2. Unsuitable for auricular acupressure: local auricular skin damage/infection/allergy to Vaccaria seeds or tape
  3. Currently receiving other acupuncture/acupressure interventions, or unable to discontinue during the study period
  4. Unsuitable for acupuncture: bleeding tendency (e.g., coagulopathy, purpura), or local acupoint damage
  5. Severe cardiac, hepatic, or renal failure, or cachexia
  6. Pregnant or breastfeeding women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
216 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Participants receive personalized acupuncture intervention (acupuncture and/or auricular acupressure) determined through the Shared Decision Making three-stage conversation model, on top of standard care. Patients choose either hospital-based or hospital-community-family intervention sub-group based on personal needs and service accessibility. Treatment duration: 8 weeks intervention + 4 weeks follow-up.

  • No intervention
    Control Group

    Participants receive standard care only, including diet, exercise, emotional regulation guidance, and health education based on the Breast Cancer Psychosomatic Health Education Manual. No active acupuncture intervention for psychosomatic symptoms during the study period.

Interventions

  • OtherAcupuncture

    Acupuncture treatment can include acupuncture and auricular point sticking. Those who choose the acupuncture scheme, complete the treatment according to the acupuncture prescription, frequency and course of treatment stipulated in this scheme ; for those who choose the auricular point sticking scheme, the sticking, replacement and daily pressing are completed according to the provisions of this scheme ; those who chose the combined scheme received acupuncture and auricular point sticking at the same time. No matter which plan was selected, the hospital intervention subgroup and the medical-social-family intervention subgroup all performed the same treatment objectives, prescription principles, course of treatment and safety requirements.

06

What researchers measure

Primary outcomes

  1. Functional Assessment of Cancer Therapy-Breast, FACT-B

    Instruments for assessing Quality of Life (QoL) among breast cancer patients;Functional Assessment of Cancer Therapy-Breast (FACT-B Version 4.0) Uniform response options: 0 = Not at all, 1 = A little bit, 2 = Somewhat, 3 = Quite a bit, 4 = Very much Unified scoring rule for all subscales and total scores: Higher scores indicate better quality of life among breast cancer patients; lower scores reflect more severe physical, emotional, social and breast-specific distress.

    Time frame: 8 weeks

Secondary outcomes

  1. Hospital anxiety and depression scale,HADS

    Hospital Anxiety and Depression Scale (HADS) Full Scoring Standard Specifications Subscale 1: Anxiety subscale (HADS-A) Number of items: 7 Minimum score: 0 Maximum score: 21 Interpretation: Higher scores mean more severe anxiety symptoms. Subscale 2: Depression subscale (HADS-D) Number of items: 7 Minimum score: 0 Maximum score: 21 Interpretation: Higher scores mean more severe depressive symptoms. HADS total score Composition: HADS-A score + HADS-D score Minimum score: 0 Maximum score: 42 Interpretation: Higher total scores indicate more severe combined anxiety and depression symptoms. Supplementary Response Option Rule (Standard HADS 4-point Likert) All items adopt 4-point scoring from 0 to 3; higher single item scores stand for worse emotional conditions.

    Time frame: 8 weeks

  2. Pittsburgh sleep quality index,PSQI

    Pittsburgh Sleep Quality Index (PSQI) Full Scoring Standard Description PSQI component subscores (7 sleep dimensions) Each component score range: 0-3 PSQI global total score Full name: Pittsburgh Sleep Quality Index Global Score Minimum score: 0 Maximum score: 21 Interpretation: Higher global scores represent worse overall sleep quality; lower scores indicate better sleep quality.

    Time frame: 8 weeks

  3. Brief Fatigue Inventory,BFI

    Brief Fatigue Inventory (BFI) Full Scoring Standard Description Single item scoring range for each fatigue item: 0-10 BFI Global Fatigue Severity Score Full name: Brief Fatigue Inventory Global Fatigue Severity Score Minimum score: 0 Maximum score: 10 Interpretation: Higher scores indicate more severe fatigue; lower scores represent milder fatigue status. Supplement The total global score is the average of all 9 items of the BFI. Each item uses a 0-10 numerical rating scale, where 0 = no fatigue at all and 10 = worst fatigue imaginable.

    Time frame: 8 weeks

  4. Brief Pain Inventory,BPI

    Brief Pain Inventory (BPI) Full Scoring Standard Description Single item scoring range: Each pain-related item is scored on a 0-10 numeric rating scale (0 = no pain, 10 = worst pain imaginable) BPI Pain Severity Score Full name: Brief Pain Inventory Pain Severity Score Composition: Average score of 4 pain severity items (worst pain, least pain, average pain, pain right now) Minimum score: 0 Maximum score: 10 Interpretation: Higher scores mean greater pain severity BPI Pain Interference Score Full name: Brief Pain Inventory Pain Interference Score Composition: Average score of 7 pain interference items (interference with general activity, mood, walking ability, normal work, relations with others, sleep, enjoyment of life) Minimum score: 0 Maximum score: 10 Interpretation: Higher scores indicate more severe interference of pain on daily life

    Time frame: 8 weeks

Other outcomes

  1. Acceptability of the intervention

    Acceptability of the intervention is assessed using a 4-item, 5-point Likert scale. Each item is scored from 1 to 5. The total score is calculated as the sum of the four item scores, ranging from 4 to 20. Higher scores indicate greater acceptability. A total score of ≥16 indicates good acceptability.

    Time frame: 8 weeks

  2. Feasibility of the intervention

    Feasibility of the intervention is assessed using a 4-item, 5-point Likert scale. Each item is scored from 1 to 5. The total score is calculated as the sum of the four item scores, ranging from 4 to 20. Higher scores indicate greater feasibility. A total score of ≥16 indicates good feasibility.

    Time frame: 8 weeks

  3. Implementation Fidelity: Auricular Acupressure Treatment Adherence Rate

    Auricular acupressure treatment adherence rate = (Number of auricular acupressure sessions actually completed / Number of required sessions) × 100%. An adherence rate of ≥80% indicates good adherence.

    Time frame: 8 weeks

  4. Implementation Fidelity: Self-Pressing Adherence Rate

    Self-pressing adherence was assessed by recording the daily frequency of self-pressing in patient logs and verifying the records by asking participants during follow-up visits. An adherence rate of ≥90% indicates good adherence.

    Time frame: 8 weeks

  5. Coverage of the intervention

    Coverage was defined as the proportion of eligible breast cancer patients with psychosomatic symptoms who participated in the study.

    Time frame: 8 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2028, 26 months later.

Of 2,664 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 26 months is below that.

Counting every sponsor, half of 2,774 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2026
First posted
Nov 17, 2026
StartEst.
Oct 30, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07942103
Lead sponsor
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Collaborators
Tianjin Medical University Cancer Institute and Hospital, Tianjin University of Traditional Chinese Medicine, Guangkai Street Community Health Service Center, Nankai District, Tianjin, Xingnan Street Community Health Service Center, Nankai District, Tianjin, Xinzhuang Town Health Center, Jinnan District, Tianjin
Responsible party
Li Li (Associate Research Fellow, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine) — Principal investigator
First posted
Nov 17, 2026
Start date
Oct 30, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Li Li
Contact
lilitcm@foxmail.com
+86 18222626653

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion